AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001A83

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Identifieur interne : 001A83 ( PascalFrancis/Corpus ); précédent : 001A82; suivant : 001A84

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Auteurs : H. Ascher-Svanum ; X. Peng ; W. Montgomery ; D. E. Faries ; A. H. Lawson ; M. M. Witte ; D. Novick ; N. Jemiai ; E. Perrin ; D. P. Mcdonnell

Source :

European psychiatry [ 0924-9338 ] ; 2011.

RBID : Pascal:11-0339142

Descripteurs français

Pascal (Inist)
- Evaluation, Voie orale, Neuroleptique, Olanzapine, Forme libération contrôlée, Traitement, Schizophrénie, Psychotrope, Antipsychotique atypique, Forme pharmaceutique.

English descriptors

KwdEn :
- Atypical antipsychotic, Controlled release form, Dosage form, Evaluation, Neuroleptic, Olanzapine, Oral administration, Psychotropic, Schizophrenia, Treatment.

Abstract

Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0924-9338`
A03		`1`		`@0 Eur. psychiatr.`
A05				`@2 26`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia`
A11	`01`	`1`		`@1 ASCHER-SVANUM (H.)`
A11	`02`	`1`		`@1 PENG (X.)`
A11	`03`	`1`		`@1 MONTGOMERY (W.)`
A11	`04`	`1`		`@1 FARIES (D. E.)`
A11	`05`	`1`		`@1 LAWSON (A. H.)`
A11	`06`	`1`		`@1 WITTE (M. M.)`
A11	`07`	`1`		`@1 NOVICK (D.)`
A11	`08`	`1`		`@1 JEMIAI (N.)`
A11	`09`	`1`		`@1 PERRIN (E.)`
A11	`10`	`1`		`@1 MCDONNELL (D. P.)`
A14	`01`			`@1 Lilly Corporate Center, DC 4133, Eli Lilly and Company @2 Indianapolis, IN 46285 @3 USA @Z 1 aut. @Z 2 aut. @Z 5 aut.`
A14	`02`			`@1 Eli Lilly Australia Pty Ltd, 112, Wharf Road @2 West Ryde NSW 2114 @3 AUS @Z 3 aut.`
A14	`03`			`@1 Lilly USA, LLC, Lilly Corporate Center, DC 4133 @2 Indianapolis, IN 46285 @3 USA @Z 6 aut.`
A14	`04`			`@1 Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham @2 Surrey, GU20 6PH @3 GBR @Z 7 aut. @Z 8 aut.`
A14	`05`			`@1 Eli Lilly and Company Limited, 13, rue Pagès @2 92158 Suresnes @3 FRA @Z 9 aut.`
A14	`06`			`@1 Eli Lilly and Company Limited, Cork ELCL @2 DC 6158 @3 GBR @Z 10 aut.`
A14	`07`			`@1 Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024 @2 Indianapolis, IN 46285 @3 USA @Z 4 aut.`
A20				`@1 313-319`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21224 @5 354000509415590080`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 33 ref.`
A47	`01`	`1`		`@0 11-0339142`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 European psychiatry`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.
C02	`01`	`X`		`@0 002B18C06A`
C02	`02`	`X`		`@0 002B02B03`
C03	`01`	`X`	`FRE`	`@0 Evaluation @5 01`
C03	`01`	`X`	`ENG`	`@0 Evaluation @5 01`
C03	`01`	`X`	`SPA`	`@0 Evaluación @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie orale @5 02`
C03	`02`	`X`	`ENG`	`@0 Oral administration @5 02`
C03	`02`	`X`	`SPA`	`@0 Vía oral @5 02`
C03	`03`	`X`	`FRE`	`@0 Neuroleptique @5 03`
C03	`03`	`X`	`ENG`	`@0 Neuroleptic @5 03`
C03	`03`	`X`	`SPA`	`@0 Neuroléptico @5 03`
C03	`04`	`X`	`FRE`	`@0 Olanzapine @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Olanzapine @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Olanzapina @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Forme libération contrôlée @5 05`
C03	`05`	`X`	`ENG`	`@0 Controlled release form @5 05`
C03	`05`	`X`	`SPA`	`@0 Forma liberación controlada @5 05`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 06`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 06`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 06`
C03	`07`	`X`	`FRE`	`@0 Schizophrénie @5 07`
C03	`07`	`X`	`ENG`	`@0 Schizophrenia @5 07`
C03	`07`	`X`	`SPA`	`@0 Esquizofrenia @5 07`
C03	`08`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 31`
C03	`08`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 31`
C03	`08`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 31`
C03	`09`	`X`	`FRE`	`@0 Antipsychotique atypique @5 32`
C03	`09`	`X`	`ENG`	`@0 Atypical antipsychotic @5 32`
C03	`09`	`X`	`SPA`	`@0 Antipsicótico atípico @5 32`
C03	`10`	`X`	`FRE`	`@0 Forme pharmaceutique @5 33`
C03	`10`	`X`	`ENG`	`@0 Dosage form @5 33`
C03	`10`	`X`	`SPA`	`@0 Forma farmacéutica @5 33`
C07	`01`	`X`	`FRE`	`@0 Antagoniste dopamine @5 37`
C07	`01`	`X`	`ENG`	`@0 Dopamine antagonist @5 37`
C07	`01`	`X`	`SPA`	`@0 Antagonista dopamina @5 37`
C07	`02`	`X`	`FRE`	`@0 Antagoniste sérotonine @5 38`
C07	`02`	`X`	`ENG`	`@0 Serotonin antagonist @5 38`
C07	`02`	`X`	`SPA`	`@0 Antagonista serotonina @5 38`
C07	`03`	`X`	`FRE`	`@0 Dérivé de la dibenzodiazépine @5 39`
C07	`03`	`X`	`ENG`	`@0 Dibenzodiazepine derivatives @5 39`
C07	`03`	`X`	`SPA`	`@0 Dibenzodiazepina derivado @5 39`
C07	`04`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 40`
C07	`04`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 40`
C07	`04`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 40`
C07	`05`	`X`	`FRE`	`@0 Récepteur sérotoninergique @5 41`
C07	`05`	`X`	`ENG`	`@0 Serotonine receptor @5 41`
C07	`05`	`X`	`SPA`	`@0 Receptor serotoninérgico @5 41`
C07	`06`	`X`	`FRE`	`@0 Dérivé de la thiénobenzodiazépine @5 42`
C07	`06`	`X`	`ENG`	`@0 Thienobenzodiazepine derivatives @5 42`
C07	`06`	`X`	`SPA`	`@0 Tienobenzodiazepina derivado @5 42`
C07	`07`	`X`	`FRE`	`@0 Psychose @5 43`
C07	`07`	`X`	`ENG`	`@0 Psychosis @5 43`
C07	`07`	`X`	`SPA`	`@0 Psicosis @5 43`
N21				`@1 234`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0339142 INIST
ET :	Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
AU :	ASCHER-SVANUM (H.); PENG (X.); MONTGOMERY (W.); FARIES (D. E.); LAWSON (A. H.); WITTE (M. M.); NOVICK (D.); JEMIAI (N.); PERRIN (E.); MCDONNELL (D. P.)
AF :	Lilly Corporate Center, DC 4133, Eli Lilly and Company/Indianapolis, IN 46285/Etats-Unis (1 aut., 2 aut., 5 aut.); Eli Lilly Australia Pty Ltd, 112, Wharf Road/West Ryde NSW 2114/Australie (3 aut.); Lilly USA, LLC, Lilly Corporate Center, DC 4133/Indianapolis, IN 46285/Etats-Unis (6 aut.); Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham/Surrey, GU20 6PH/Royaume-Uni (7 aut., 8 aut.); Eli Lilly and Company Limited, 13, rue Pagès/92158 Suresnes/France (9 aut.); Eli Lilly and Company Limited, Cork ELCL/DC 6158/Royaume-Uni (10 aut.); Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024/Indianapolis, IN 46285/Etats-Unis (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	European psychiatry; ISSN 0924-9338; France; Da. 2011; Vol. 26; No. 5; Pp. 313-319; Bibl. 33 ref.
LA :	Anglais
EA :	Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.
CC :	002B18C06A; 002B02B03
FD :	Evaluation; Voie orale; Neuroleptique; Olanzapine; Forme libération contrôlée; Traitement; Schizophrénie; Psychotrope; Antipsychotique atypique; Forme pharmaceutique
FG :	Antagoniste dopamine; Antagoniste sérotonine; Dérivé de la dibenzodiazépine; Récepteur dopaminergique D2; Récepteur sérotoninergique; Dérivé de la thiénobenzodiazépine; Psychose
ED :	Evaluation; Oral administration; Neuroleptic; Olanzapine; Controlled release form; Treatment; Schizophrenia; Psychotropic; Atypical antipsychotic; Dosage form
EG :	Dopamine antagonist; Serotonin antagonist; Dibenzodiazepine derivatives; D2 Dopamine receptor; Serotonine receptor; Thienobenzodiazepine derivatives; Psychosis
SD :	Evaluación; Vía oral; Neuroléptico; Olanzapina; Forma liberación controlada; Tratamiento; Esquizofrenia; Psicotropo; Antipsicótico atípico; Forma farmacéutica
LO :	INIST-21224.354000509415590080
ID :	11-0339142

Links to Exploration step

Pascal:11-0339142

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</title>
<author><name sortKey="Ascher Svanum, H" sort="Ascher Svanum, H" uniqKey="Ascher Svanum H" first="H." last="Ascher-Svanum">H. Ascher-Svanum</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng, X" sort="Peng, X" uniqKey="Peng X" first="X." last="Peng">X. Peng</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montgomery, W" sort="Montgomery, W" uniqKey="Montgomery W" first="W." last="Montgomery">W. Montgomery</name>
<affiliation><inist:fA14 i1="02"><s1>Eli Lilly Australia Pty Ltd, 112, Wharf Road</s1>
<s2>West Ryde NSW 2114</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Faries, D E" sort="Faries, D E" uniqKey="Faries D" first="D. E." last="Faries">D. E. Faries</name>
<affiliation><inist:fA14 i1="07"><s1>Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lawson, A H" sort="Lawson, A H" uniqKey="Lawson A" first="A. H." last="Lawson">A. H. Lawson</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Witte, M M" sort="Witte, M M" uniqKey="Witte M" first="M. M." last="Witte">M. M. Witte</name>
<affiliation><inist:fA14 i1="03"><s1>Lilly USA, LLC, Lilly Corporate Center, DC 4133</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Novick, D" sort="Novick, D" uniqKey="Novick D" first="D." last="Novick">D. Novick</name>
<affiliation><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jemiai, N" sort="Jemiai, N" uniqKey="Jemiai N" first="N." last="Jemiai">N. Jemiai</name>
<affiliation><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perrin, E" sort="Perrin, E" uniqKey="Perrin E" first="E." last="Perrin">E. Perrin</name>
<affiliation><inist:fA14 i1="05"><s1>Eli Lilly and Company Limited, 13, rue Pagès</s1>
<s2>92158 Suresnes</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, D P" sort="Mcdonnell, D P" uniqKey="Mcdonnell D" first="D. P." last="Mcdonnell">D. P. Mcdonnell</name>
<affiliation><inist:fA14 i1="06"><s1>Eli Lilly and Company Limited, Cork ELCL</s1>
<s2>DC 6158</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0339142</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0339142 INIST</idno>
<idno type="RBID">Pascal:11-0339142</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</title>
<author><name sortKey="Ascher Svanum, H" sort="Ascher Svanum, H" uniqKey="Ascher Svanum H" first="H." last="Ascher-Svanum">H. Ascher-Svanum</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Peng, X" sort="Peng, X" uniqKey="Peng X" first="X." last="Peng">X. Peng</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Montgomery, W" sort="Montgomery, W" uniqKey="Montgomery W" first="W." last="Montgomery">W. Montgomery</name>
<affiliation><inist:fA14 i1="02"><s1>Eli Lilly Australia Pty Ltd, 112, Wharf Road</s1>
<s2>West Ryde NSW 2114</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Faries, D E" sort="Faries, D E" uniqKey="Faries D" first="D. E." last="Faries">D. E. Faries</name>
<affiliation><inist:fA14 i1="07"><s1>Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lawson, A H" sort="Lawson, A H" uniqKey="Lawson A" first="A. H." last="Lawson">A. H. Lawson</name>
<affiliation><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Witte, M M" sort="Witte, M M" uniqKey="Witte M" first="M. M." last="Witte">M. M. Witte</name>
<affiliation><inist:fA14 i1="03"><s1>Lilly USA, LLC, Lilly Corporate Center, DC 4133</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Novick, D" sort="Novick, D" uniqKey="Novick D" first="D." last="Novick">D. Novick</name>
<affiliation><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jemiai, N" sort="Jemiai, N" uniqKey="Jemiai N" first="N." last="Jemiai">N. Jemiai</name>
<affiliation><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perrin, E" sort="Perrin, E" uniqKey="Perrin E" first="E." last="Perrin">E. Perrin</name>
<affiliation><inist:fA14 i1="05"><s1>Eli Lilly and Company Limited, 13, rue Pagès</s1>
<s2>92158 Suresnes</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, D P" sort="Mcdonnell, D P" uniqKey="Mcdonnell D" first="D. P." last="Mcdonnell">D. P. Mcdonnell</name>
<affiliation><inist:fA14 i1="06"><s1>Eli Lilly and Company Limited, Cork ELCL</s1>
<s2>DC 6158</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European psychiatry</title>
<title level="j" type="abbreviated">Eur. psychiatr.</title>
<idno type="ISSN">0924-9338</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European psychiatry</title>
<title level="j" type="abbreviated">Eur. psychiatr.</title>
<idno type="ISSN">0924-9338</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atypical antipsychotic</term>
<term>Controlled release form</term>
<term>Dosage form</term>
<term>Evaluation</term>
<term>Neuroleptic</term>
<term>Olanzapine</term>
<term>Oral administration</term>
<term>Psychotropic</term>
<term>Schizophrenia</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Evaluation</term>
<term>Voie orale</term>
<term>Neuroleptique</term>
<term>Olanzapine</term>
<term>Forme libération contrôlée</term>
<term>Traitement</term>
<term>Schizophrénie</term>
<term>Psychotrope</term>
<term>Antipsychotique atypique</term>
<term>Forme pharmaceutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0924-9338</s0>
</fA01>
<fA03 i2="1"><s0>Eur. psychiatr.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ASCHER-SVANUM (H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PENG (X.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MONTGOMERY (W.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FARIES (D. E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LAWSON (A. H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WITTE (M. M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>NOVICK (D.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>JEMIAI (N.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>PERRIN (E.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MCDONNELL (D. P.)</s1>
</fA11>
<fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Eli Lilly Australia Pty Ltd, 112, Wharf Road</s1>
<s2>West Ryde NSW 2114</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Lilly USA, LLC, Lilly Corporate Center, DC 4133</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Eli Lilly and Company Limited, 13, rue Pagès</s1>
<s2>92158 Suresnes</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Eli Lilly and Company Limited, Cork ELCL</s1>
<s2>DC 6158</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>313-319</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21224</s2>
<s5>354000509415590080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0339142</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>European psychiatry</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B18C06A</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Evaluation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Evaluation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Evaluación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Olanzapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Forme libération contrôlée</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Controlled release form</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Forma liberación controlada</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Schizophrénie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Schizophrenia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Esquizofrenia</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>31</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>31</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>31</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antipsychotique atypique</s0>
<s5>32</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Atypical antipsychotic</s0>
<s5>32</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antipsicótico atípico</s0>
<s5>32</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Forme pharmaceutique</s0>
<s5>33</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Dosage form</s0>
<s5>33</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Forma farmacéutica</s0>
<s5>33</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Antagoniste sérotonine</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Serotonin antagonist</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Antagonista serotonina</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Dérivé de la dibenzodiazépine</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Dibenzodiazepine derivatives</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Dibenzodiazepina derivado</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Récepteur sérotoninergique</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Serotonine receptor</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Receptor serotoninérgico</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Dérivé de la thiénobenzodiazépine</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Thienobenzodiazepine derivatives</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Tienobenzodiazepina derivado</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Psychose</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>43</s5>
</fC07>
<fN21><s1>234</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0339142 INIST</NO>
<ET>Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</ET>
<AU>ASCHER-SVANUM (H.); PENG (X.); MONTGOMERY (W.); FARIES (D. E.); LAWSON (A. H.); WITTE (M. M.); NOVICK (D.); JEMIAI (N.); PERRIN (E.); MCDONNELL (D. P.)</AU>
<AF>Lilly Corporate Center, DC 4133, Eli Lilly and Company/Indianapolis, IN 46285/Etats-Unis (1 aut., 2 aut., 5 aut.); Eli Lilly Australia Pty Ltd, 112, Wharf Road/West Ryde NSW 2114/Australie (3 aut.); Lilly USA, LLC, Lilly Corporate Center, DC 4133/Indianapolis, IN 46285/Etats-Unis (6 aut.); Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham/Surrey, GU20 6PH/Royaume-Uni (7 aut., 8 aut.); Eli Lilly and Company Limited, 13, rue Pagès/92158 Suresnes/France (9 aut.); Eli Lilly and Company Limited, Cork ELCL/DC 6158/Royaume-Uni (10 aut.); Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024/Indianapolis, IN 46285/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>European psychiatry; ISSN 0924-9338; France; Da. 2011; Vol. 26; No. 5; Pp. 313-319; Bibl. 33 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.</EA>
<CC>002B18C06A; 002B02B03</CC>
<FD>Evaluation; Voie orale; Neuroleptique; Olanzapine; Forme libération contrôlée; Traitement; Schizophrénie; Psychotrope; Antipsychotique atypique; Forme pharmaceutique</FD>
<FG>Antagoniste dopamine; Antagoniste sérotonine; Dérivé de la dibenzodiazépine; Récepteur dopaminergique D2; Récepteur sérotoninergique; Dérivé de la thiénobenzodiazépine; Psychose</FG>
<ED>Evaluation; Oral administration; Neuroleptic; Olanzapine; Controlled release form; Treatment; Schizophrenia; Psychotropic; Atypical antipsychotic; Dosage form</ED>
<EG>Dopamine antagonist; Serotonin antagonist; Dibenzodiazepine derivatives; D2 Dopamine receptor; Serotonine receptor; Thienobenzodiazepine derivatives; Psychosis</EG>
<SD>Evaluación; Vía oral; Neuroléptico; Olanzapina; Forma liberación controlada; Tratamiento; Esquizofrenia; Psicotropo; Antipsicótico atípico; Forma farmacéutica</SD>
<LO>INIST-21224.354000509415590080</LO>
<ID>11-0339142</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0339142
   |texte=   Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri